Mount Sinai Health System today announced that they will be among the first in the world to deploy blood-based biomarkers (blood tests) and confirmatory tests for Alzheimer’s disease and related dementias to patients across primary and specialty care settings–early detection tools that have never before been offered to patients in the clinical setting–as part of the Davos Alzheimer’s Collaborative (DAC) Healthcare System Preparedness Accurate Diagnosis project.
